Galectins in prostate and bladder cancer: tumorigenic roles and clinical opportunities

Area of Science:

• Uro-oncology
• Cancer Biology
• Molecular Oncology

Background:

• Advanced prostate and bladder cancers represent significant unmet clinical needs due to high prevalence and limited effective treatments.
• Galectins, a family of beta-galactoside-binding proteins, are frequently dysregulated in various cancers, influencing tumor development, progression, and immune evasion.
• Altered galectin expression and aberrant glycosylation are observed in prostate and bladder cancers, contributing to malignant transformation.

Purpose of the Study:

• To investigate the role of galectin family proteins in the development and progression of advanced prostate and bladder cancers.
• To explore how altered galectin expression impacts tumor microenvironment and immune evasion in urological malignancies.
• To identify potential therapeutic targets by understanding galectin involvement in cancer pathogenesis.

Main Methods:

• Review of existing literature on galectin family members in prostate and bladder cancer.
• Analysis of gene expression data and protein levels of galectins in tumor samples.
• Investigation of galectin interactions within the tumor microenvironment and their effect on immune cells.

Main Results:

• Specific galectin members show altered expression patterns in advanced prostate and bladder cancers.
• Aberrant glycosylation associated with galectin dysregulation contributes to tumor cell transformation and progression.
• Galectins influence immune evasion mechanisms within the tumor microenvironment of these urological cancers.

Conclusions:

• Galectin family proteins are implicated in the pathogenesis of advanced prostate and bladder cancer.
• Understanding galectin roles provides crucial insights into tumor development, progression, and immune evasion.
• Targeting galectins may offer novel therapeutic strategies for managing these challenging urological malignancies.